South Korea’s Biohealth Innovation Commission, a pan-government entity tasked to act as a "control tower," is set to officially launch soon in an attempt to to more comprehensively and systematically coordinate currently fragmented policies and strategies in the sector.
But setting up a new commission is unlikely itself to complete the governance system to enable the country's biopharma industry to leap forward